臨床婦人科産科74巻12号

2020年12月発行

今月の臨床 着床環境の改善はどこまで可能か？―エキスパートに聞く最新研究と具体的対処法

子宮内免疫

免疫が着床に及ぼす影響―Th1/Th2比，NK細胞

著者： 福井淳史¹ 麦楚嫻¹ 柴原浩章¹

所属機関： ¹兵庫医科大学産科婦人科

ページ範囲：P.1246 - P.1251

文献概要

●妊娠の成立・維持においてNK細胞やT細胞などの免疫担当細胞は，末梢血中や子宮内膜・脱落膜に存在し，子宮における免疫機構の維持に重要な役割を果たしている．

●NK細胞の細胞傷害性の増加，サイトカイン産生の異常は不育症や着床不全を引き起こす．また，精液に曝露されることにより起こるNK細胞機能異常もありうる．

●不育症や着床不全に対して子宮内免疫異常に着目したさまざまな免疫学的アプローチが行われており，有効な治療法となる可能性があるが，十分なエビデンスは得られていない．

参考文献

1）Kwak-Kim JY, et al : Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF. Hum Reprod 18 : 767-773, 2003

2）Wegmann TG, et al : Bidirectional cytokine interactions in the maternal-fetal relationship : is successful pregnancy a TH2 phenomenon? Immunol Today 14 : 353-356, 1993

3）Saito S, et al : Distribution of Th1, Th2, and Th0 and the Th1/Th2 cell ratios in human peripheral and endometrial T cells. Am J Reprod Immunol 42 : 240-245, 1999

4）Fukui A, et al : Natural killer cell subpopulations and cytotoxicity for infertile patients undergoing in vitro fertilization. Am J Reprod Immunol 41 : 413-422, 1999

5）Fukui A, et al : Expression of natural cytotoxicity receptors and a2V-ATPase on peripheral blood NK cell subsets in women with recurrent spontaneous abortions and implantation failures. Am J Reprod Immunol 56 : 312-320, 2006

6）Fukui A, et al : Expression of natural cytotoxicity receptors and cytokine production on endometrial natural killer cells in women with recurrent pregnancy loss or implantation failure, and the expression of natural cytotoxicity receptors on peripheral blood natural killer cells in pregnant women with a history of recurrent pregnancy loss. J Obstet Gynaecol Res 43 : 1678-1686, 2017

7）Sargent IL, et al : NK cells and pre-eclampsia. J Reprod Immunol 76 : 40-44, 2007

8）Fukui A, et al : Intracellular cytokine expression of peripheral blood natural killer cell subsets in women with recurrent spontaneous abortions and implantation failures. Fertil Steril 89 : 157-165, 2008

9）Fukui A, et al : Correlation between natural cytotoxicity receptors and intracellular cytokine expression of peripheral blood NK cells in women with recurrent pregnancy losses and implantation failures. Am J Reprod Immunol 62 : 371-380, 2009

10）Taima A, et al : A semen-based stimulation method to analyze cytokine production by uterine CD56（bright）natural killer cells in women with recurrent pregnancy loss. J Reprod Immunol 142 : 103206, 2020

11）Nakagawa K, et al : Immunosuppressive treatment using tacrolimus promotes pregnancy outcome in infertile women with repeated implantation failures. Am J Reprod Immunol 78 : e12682, 2017

12）Ghasemnejad-Berenji H, et al : Immunomodulatory effects of hydroxychloroquine on Th1/Th2 balance in women with repeated implantation failure. Biomed Pharmacother 107 : 1277-1285, 2018

13）Ahmadi M, et al : Effect of Intravenous immunoglobulin on Th1 and Th2 lymphocytes and improvement of pregnancy outcome in recurrent pregnancy loss（RPL）. Biomed Pharmacother 92 : 1095-1102, 2017

14）Achilli C, et al : The role of immunotherapy in in vitro fertilization and recurrent pregnancy loss : a systematic review and meta-analysis. Fertil Steril 110 : 1089-1100, 2018

15）福井淳史 : 流産の原因と対策　免疫機構から見た流産の病態解明とその対策．日産婦会誌63 : 2167-2184, 2011

16）Ota K, et al : Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity. Hum Reprod 29 : 208-219, 2014

17）Ota K, et al : 1,25-dihydroxy-vitamin D3 regulates NK-cell cytotoxicity, cytokine secretion and degranulation in women with recurrent pregnancy losses. Eur J Immunol 45 : 3188-3199, 2015

18）Tevkin S, et al : The frequency of clinical pregnancy and implantation rate after cultivation of embryos in a medium with granulocyte macrophage colony-stimulating factor（GM-CSF）in patients with preceding failed attempts of ART. Gynecol Endocrinol 30 （Suppl 1） : 9-12, 2014

19）Kwak-Kim J, et al : COVID-19 and immunomodulation treatment for women with reproductive failures. J Reprod Immunol 141 : 103168, 2020